Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:MCUJF

Medicure Q1 2026 Earnings Results & Report

Medicure logo
$2.76 -0.04 (-1.43%)
As of 10/14/2026 03:58 PM Eastern

Medicure beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 21, 2026. The company reported EPS of -$0.03 versus the -$0.0439 consensus estimate, while revenue of $5.79 million topped the $3.63 million estimate by $2.16 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Medicure EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.0439
Beat/Miss
Beat by +$0.0139
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.79 million
Expected Revenue
$3.63 million
Beat/Miss
Beat by +$2.16 million
YoY Revenue Growth
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Q1 2026 Earnings FAQ

Medicure (OTCMKTS:MCUJF) reported earnings of -$0.03 per share for Q1 2026, beating the consensus estimate of -$0.0439. The report was announced on Thursday, May 21, 2026.

Medicure reported revenue of $5.79 million for Q1 2026, against a consensus estimate of $3.63 million.

Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page.

Medicure Earnings Headlines

Medicure (OTCMKTS:MCUJF) Stock Crosses Above 50 Day Moving Average - What's Next?
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105044
MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS
October 1, 2026  |  marketscreener.comM
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
 |  InvestorPlace (Ad)
Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
September 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69697627-medicure-inc-medicure-announces-completion-of-enrollment-in-its-mend-pnpo-phase-3-clinical-trial-200.htm
Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
May 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q1-2026-210021888.html
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68566676-medicure-inc-medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call-200.htm
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings.

Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate.

Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.

View Medicure Profile
Earnings Tools